Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,335 | 4,820 | 2,355 | 4,889 | 8,016 |
| Inventories | 2,758 | 2,758 | 2,735 | 2,645 | 2,634 |
| TOTAL | $6,398 | $8,084 | $5,519 | $8,024 | $11,565 |
| Non-Current Assets | |||||
| PPE Net | 161 | 193 | 228 | 236 | 231 |
| Other Non-Current Assets | 1,044 | 968 | 908 | 1,014 | 548 |
| TOTAL | $1,205 | $1,161 | $1,136 | $1,250 | $778 |
| Total Assets | $7,603 | $9,245 | $6,655 | $9,274 | $12,343 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 29 | 29 | 29 | 29 | N/A |
| Accounts payable and accrued liabilities | 1,972 | 1,842 | 1,646 | 1,523 | 1,558 |
| TOTAL | $2,170 | $2,033 | $1,832 | $1,704 | $1,705 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 29 |
| Other Non-Current Liabilities | 237 | 281 | 324 | 366 | 406 |
| TOTAL | $237 | $281 | $324 | $366 | $434 |
| Total Liabilities | $2,407 | $2,314 | $2,156 | $2,070 | $2,139 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5 | 4 | 4 | 2 | 2 |
| Common Shares | 1 | 1 | 0 | 0 | 6 |
| Retained earnings | -90,471 | -87,370 | -84,813 | -81,870 | -78,580 |
| Other shareholders' equity | 2 | 3 | 4 | 6 | 9 |
| TOTAL | $5,196 | $6,931 | $4,499 | $7,205 | $10,203 |
| Total Liabilities And Equity | $7,603 | $9,245 | $6,655 | $9,274 | $12,343 |